Tougher on cancer, not on patients

Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.

Learn More →

An illustration showing the anatomy or a payload linker

The A in ADC, amplified

Antibody-drug conjugates are a potent modality in need of improvement. Whether it’s successfully treating more patients or overcoming drug resistance, we need new designs for ADCs.

By transforming how the antibody interacts with tumour cells, our next-generation bispecific ADCs are more potent only where it matters. This allows us to address diseases that current options can’t treat.

AND-GATE

OR-GATE

V-GATE

A whole new logic to treating cancer cells: V-gate

Bispecific antibody-drug conjugates allow for “gating” of how the therapeutic binds to a cancer cell based on the presence of either or both of two molecular targets on the surface of the cell.

At Valink, we go beyond binary gating. We discover and develop drugs that respond more effectively tuned to continuous levels of each target, whether in cancer or other diseases. We call this approach “V-Gate".

Three members of our team working hard in the lab

Our mission

Our Mission is to build more effective drugs that can differentiate disease from healthy cells. We will create drugs that minimise side effects, enable new payloads and cure more people.

Learn more about our team →

The LiliumX™ Platform

Valink is powered by the LiliumX® platform, a proprietary discovery engine built on three pillars: synthetic protein biology, high-throughput functional screening, and AI. This platform broadly explores the field of bispecific ADCs to identify potential drugs no one else can find.

Learn more on our technology page →